BiotechTube

CBL-514 Injection

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Subcutaneous Fat

Conditions

Subcutaneous Fat

Trial Timeline

May 30, 2023 → May 20, 2024

NCT ID
NCT05736107

About CBL-514 Injection

CBL-514 Injection is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT05736107. Target conditions include Subcutaneous Fat.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT07140939Phase 3Recruiting
NCT05736107Phase 2Completed
NCT05836779Phase 2Completed
NCT04897412Phase 2Completed

Competing Products

9 competing products in Subcutaneous Fat

See all competitors
ProductCompanyStageHype Score
TR-701 FA + LinezolidMerckPhase 3
77
TR-701 FA + LinezolidMerckPhase 3
77
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514 InjectionCaliway BiopharmaceuticalsPhase 2
51
CBL-514, placebo + CBL-514, placebo + CBL-514Caliway BiopharmaceuticalsPhase 1
32
CBL-514 InjectionCaliway BiopharmaceuticalsPhase 3
76
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514Caliway BiopharmaceuticalsPhase 2
51
CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium ChlorideCaliway BiopharmaceuticalsPhase 2
51

Other Products from Caliway Biopharmaceuticals

CBL-514 InjectionPhase 3
76
CBL-514Phase 2
51
CBL-514 InjectionPhase 2
51
CBL-514 injectionPhase 2
51
10 mg CBL-514 per injection + 15 mg CBL-514 per injectionPhase 2
51